-

LivaNova to Announce Third-Quarter 2024 Results

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024 at 12 p.m. London time (8 a.m. Eastern Time). The Company will release its third-quarter 2024 results prior to the call.

A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 881946. A replay will be available on the LivaNova website for 90 days following the call.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the next Company conference call. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contacts

LivaNova Investor Relations and Media Contacts

+1 281-895-2382
Briana Gotlin
Director, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com

LivaNova PLC

NASDAQ:LIVN
Details
Headquarters: London, United Kingdom
CEO: Vladimir Makatsaria
Employees: 3000
Organization: PUB
Revenues: $1.15B (2023)
Net Income: Not Available (2023)

Release Summary
LivaNova PLC will host a conference call to discuss its third-quarter 2024 results on Wednesday, October 30, 2024.
Release Versions

Contacts

LivaNova Investor Relations and Media Contacts

+1 281-895-2382
Briana Gotlin
Director, Investor Relations
InvestorRelations@livanova.com
Deanna Wilke
VP, Corporate Communications
Corporate.Communications@livanova.com

Social Media Profiles
More News From LivaNova PLC

LivaNova to Announce First-Quarter 2025 Results

LONDON--(BUSINESS WIRE)--LivaNova PLC will host a conference call to discuss its first-quarter 2025 results on Wed., May 7, 2025, at 1 p.m. London time (8 a.m. Eastern Time)....

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

LONDON--(BUSINESS WIRE)--LivaNova PLC today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance....

LivaNova to Present at the Barclays Global Healthcare Conference

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 2:00 p.m. Eastern Time on Tuesday, March 11. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should...
Back to Newsroom